Question: On what date was the Precision Medicine Initiative announced?
Context: The International Precision Medicine Center (IPMC) - ) is the world’s first Precision Medicine Center focused on Cell Therapy that is situated in a global bio-service multi complex community in South Korea.  It is founded in March 2016 by Young Woo Jang, who is now a CEO of IPMC, and Dr. Robert Hriri, the world’s renowned pioneer of the use of human stem cells to treat a range of life-threatening diseases. The 2015 State of the Union Address was given by the 44th United States President, Barack Obama, on Tuesday, January 20, 2015, in the chamber of the United States House of Representatives.  Following recent tradition, Speaker of the House John Boehner sent a letter on December 19, 2014, formally inviting President Obama to speak (despite a proposal from some conservatives that House Republicans withhold the invitation in retaliation for Obama's executive actions on immigration reform).  It was addressed to the 114th United States Congress.  The State of the Union Address was broadcast on various television and radio stations and webcast from the White House.  Webcasts were also provided by other sponsors, including a webcast from the U.S. Republican Party. The Precision Medicine Initiative is a research project created by Barack Obama in 2015 with $215 million in funding that aims to make advances in tailoring medical care to the individual.  The project aims to collect genetic and health data from one million subjects.  The initiative was announced during the 2015 State of the Union Address and is advised by Verily Life Sciences. Rui Luís Reis is a Portuguese scientist known for his research in tissue engineering, regenerative medicine, biomaterials, biomimetics, stem cells, and biodegradable polymers.  Reis is Professor of tissue engineering, regenerative medicine and stem cells at the Department of Polymer Engineering, School of Engineering of the University of Minho.  He is the Director of the 3B's Research Group, which specializes in the areas of regenerative Medicine, tissue engineering, stem cells and biomaterials.  He is also the Director of the ICVS/3B´s Associate Laboratory of UMinho.  He is also the CEO of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine.  Rui L. Reis is also, since 2013, the Vice-Rector (Vice-President) for research of UMinho.  Since 2007 he is also editor-in-chief of the "Journal of Tissue Engineering and Regenerative Medicine".  He is since 2016 and until 2018 the Global (World) President of the Tissue Engineering and Regenerative Medicine International Society (TERMIS).  He is the responsible and PI of the EU funded project for the creation of the new center of Excelence, with headquarters in AvePark in Caldas das Taipas - Guimarães, the Discoveries Center for Regenerative and Precision Medicine in a Teaming process between University of Minho, University College London, University of Porto, University of Aveiro, University of Lisbon, University NOVA Lisbon. The White House BRAIN Initiative (Brain Research through Advancing Innovative Neurotechnologies), is a collaborative, public-private research initiative announced by the Obama administration on April 2, 2013, with the goal of supporting the development and application of innovative technologies that can create a dynamic understanding of brain function.  This activity is a Grand Challenge focused on revolutionizing our understanding of the human brain, and was developed by the White House Office of Science and Technology Policy (OSTP) as part of a broader White House Neuroscience Initiative.  Inspired by the Human Genome Project, BRAIN aims to help researchers uncover the mysteries of brain disorders, such as Alzheimer's and Parkinson's diseases, depression, and traumatic brain injury (TBI). Kathy Giusti (born 1958) is the Founder of the Multiple Myeloma Research Foundation; she now serves as a member of its Board of Directors.  Giusti is the Henry & Allison McCance Family Senior Fellow at Harvard Business School, where she serves as Faculty Co-Chair of HBS Kraft Precision Medicine Accelerator.  She is recognized as a pioneer of precision medicine, a champion of open-access data sharing, and a strong advocate for patient engagement in their treatment and care and as part of the research process. Yves A. Lussier, M.D., Professional Engineer, is a physician-scientist conducting research in Precision medicine, Translational bioinformatics and Personal Genomics.  As a co-founder of Purkinje, he pioneered the commercial use of controlled medical vocabulary organized as directed semantic networks in electronic medical records (1st clinical ontology available commercially), as well as Pen computing for clinicians.  He was invited to the White House Precision Medicine Initiative summit. Personalized medicine, also termed precision medicine, is a medical procedure that separates patients into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease.  The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept though some authors and organisations use these expressions separately to indicate particular nuances. Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, practices, or products being tailored to the individual patient.  In this model, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis.  Tools employed in precision medicine can include molecular diagnostics, imaging, and analytics. PrecisionFDA (stylized precisionFDA) is a cloud-based next-generation DNA sequencing (NGS) data platform developed by the United States Food and Drug Administration (FDA).  It was designed as part of President Barack Obama's Precision Medicine Initiative in 2015.  The platform allows researchers to upload and compare data against reference genomes, bioinformatics pipelines, and genomic data.  Users may also use the service to verify their genetic tests against reference genomes.  The platform's code is open source and available on GitHub.
Answer: January 20, 2015